Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Solid Tumors, Gastric Cancer
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.
- Conditions
- Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
- Trial name
- NCT06783569
- Testing
- JR8603
- Where
- 2 sites in China
- Volunteers
- 94 people
- Sponsor
- JiaRay Group
Metastatic Colorectal Cancer (CRC)
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
This study is open to adults with advanced bowel cancer (colorectal cancer) with a KRAS mutation. This is a study in people for whom previous treatment was not successful and surgery is not a treatment option.
- Trial name
- NCT04627142
- Testing
- BI 1701963, Camptosar®
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This study aims to evaluate the efficacy and safety of short-course radiotherapy followed by AK112 in combination with CAPOX as neoadjuvant therapy in patients with locally advanced rectal cancer
- Trial name
- NCT06802666
- Testing
- short-course radiotherapy, Ivonescimab, capecitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locally Advanced Rectal Cancer (LARC)
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
To evaluate the pathological complete response rate (pCR) of intestinal flora transplantation combined with short-course radiotherapy +CAPOX+ sintilimab in neoadjuvant therapy for locally advanced rectal cancer (pMMR/MSS type)
- Trial name
- NCT07738042
- Testing
- Sintilimab, CAPOX (oxaliplatin/capecitabine), Short-course radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
This study is a one-year, observational, prospective cohort study. For enrolled patients with newly diagnosed locally advanced rectal cancer, the treatment plan will be decided by the physician based on the 2022 NCCN Rectal…
- Trial name
- NCT07346729
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Colorectal Cancer
Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients
The study aims to identify the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with local advanced colorectal cancer.
- Trial name
- NCT02415829
- Testing
- capecitabine plus oxaliplatin
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Resectable Rectal Cancer Clinical Stage II and III
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer
A Phase II study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.
- Trial name
- NCT01152710
- Testing
- Capecitabine
- Where
- Slovenia
- Volunteers
- 57 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer Patients
Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation
To observe and evaluate the efficacy and safety of neoadjuvant long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Mesylate in the treatment of locally advanced rectal cancer and low-lying rectal…
- Trial name
- NCT07687433
- Testing
- Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Harbin Medical University
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Group B (1:1).
- Trial name
- NCT07150949
- Testing
- Long-course radiotherapy, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Unresectable Colorectal Cancer, Colorectal Cancer (Locally Advanced or Metastatic)
FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer
This clinical trial evaluates the efficacy and safety of adding fecal microbiota transplantation (FMT) to first-line standard of care for patients with initially unresectable colorectal cancer (CRC).
- Trial name
- NCT07509398
- Testing
- Standard First-Line Therapy, FMT Combined with Standard First-Line Therapy
- Volunteers
- 220 people
- Sponsor
- Shanghai 10th People's Hospital
Rectal Cancer
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial evaluates whether online adaptive radiotherapy (ART) with a sequential boost to both the primary rectal tumor and clinically involved lymph nodes improves pathologic…
- Trial name
- NCT06246344
- Testing
- Online Adaptive Radiotherapy With Sequential Boost, Conventional Non-Adaptive IMRT, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shandong Cancer Hospital and Institute
Advanced Colorectal Cancer
ANGIOPREDICT. ICORG 12-16, V3
Primary Objective: The primary objective is to validate previously identified predictive/prognostic genomic DNA and expression biomarkers of response to combination bvz treatments in K-ras mutant advanced CRC (a CRC) or…
- Trial name
- NCT01822444
- Testing
- Biomarker analysis
- Where
- 17 sites in Germany, Ireland
- Volunteers
- 76 people
- Sponsor
- Cancer Trials Ireland
Colorectal Cancer
A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents
Fruquintinib is already the standard third-line treatment for metastatic colorectal cancer, but the efficacy of fruquintinib in neoadjuvant and conversion therapy for locally advanced/advanced colorectal cancer has not yet been…
- Trial name
- NCT06470178
- Testing
- corhot1: chemotherapy combined with fruquintinib, corhot2: chemotherapy combined with fruquintinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Wuhan University
Locally Advanced Rectal Carcinoma
Endorectal Brachytherapy for Rectal Cancer
The management of rectal cancers has changed over the past decades towards a multidisciplinary strategy, combining radiotherapy, chemotherapy, and surgery.
- Trial name
- ICUREC (NCT05591534)
- Testing
- Endorectal brachytherapy
- Where
- 2 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Bordeaux
Locally Advanced Rectal Carcinoma
Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer
The goal of this clinical trial is to investigate total neoadjuvant therapy (TNT) using short course radiation therapy (SCRT) followed by full course of chemotherapy then surgery in locally advanced rectal cancer.
- Trial name
- NCT05622357
- Testing
- short course radiation therapy followed by 6 cycles of CAPOX then surgery
- Where
- Egypt
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute, Egypt
Rectal Cancer
Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)
This multicenter, randomized controlled clinical trial (FIRM02 Study) aims to evaluate the effectiveness and safety of neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor (Serplulimab) in patients with MSS/pMMR locally…
- Trial name
- NCT07381400
- Testing
- mFOLFOX6, Serplulimab
- Volunteers
- 128 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Locally Advanced Rectal Cancer
Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer
This is a single arm phase II trial with combined celecoxib, tegafur-uracil, folinate and preoperative radiotherapy for patients with locally advanced rectal cancer.
- Trial name
- NCT00931203
- Testing
- Celecoxib
- Where
- Taiwan
- Volunteers
- 55 people
- Sponsor
- National Health Research Institutes, Taiwan
Rectal Cancer, HER2-positive
Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
The purpose of this study was to evaluate the complete response rate (CR) of trastuzumab biosimilars and pertuzumab biosimilars combined with oxaliplatin and capecitabine in neoadjuvant treatment of patients with locally advanced…
- Trial name
- NePHera (NCT07108127)
- Testing
- Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking Union Medical College Hospital
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
This phase I trial studies the side effects and best dose of papaverine (PPV) when given together with radiation therapy (RT) and tests how well it works in treating patients with rectal cancer that has spread to nearby tissue or…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Trial name
- NCT06834126
- Testing
- Biospecimen Collection, Computed Tomography, Consolidation Therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center